- Home
- MDXG vs BCAX Comparison
MDXG vs BCAX Comparison
Compare MDXG & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXG
- BCAX
- Stock Information
- Founded
- MDXG 2006
- BCAX 2018
- Country
- MDXG United States
- BCAX United States
- Employees
- MDXG N/A
- BCAX N/A
- Industry
- MDXG Biotechnology: Pharmaceutical Preparations
- BCAX
- Sector
- MDXG Health Care
- BCAX
- Exchange
- MDXG Nasdaq
- BCAX NYSE
- Market Cap
- MDXG 1.1B
- BCAX 1.0B
- IPO Year
- MDXG N/A
- BCAX 2024
- Fundamental
- Price
- MDXG $9.10
- BCAX $17.59
- Analyst Decision
- MDXG Strong Buy
- BCAX Strong Buy
- Analyst Count
- MDXG 5
- BCAX 5
- Target Price
- MDXG $12.00
- BCAX $41.33
- AVG Volume (30 Days)
- MDXG 814.8K
- BCAX 594.2K
- Earning Date
- MDXG 10-30-2024
- BCAX 02-16-2025
- Dividend Yield
- MDXG N/A
- BCAX N/A
- EPS Growth
- MDXG N/A
- BCAX N/A
- EPS
- MDXG 0.52
- BCAX N/A
- Revenue
- MDXG $342,804,000.00
- BCAX N/A
- Revenue This Year
- MDXG $9.56
- BCAX N/A
- Revenue Next Year
- MDXG $9.19
- BCAX N/A
- P/E Ratio
- MDXG $18.08
- BCAX N/A
- Revenue Growth
- MDXG 10.93
- BCAX N/A
- 52 Week Low
- MDXG $5.47
- BCAX $16.01
- 52 Week High
- MDXG $10.14
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- MDXG 53.38
- BCAX N/A
- Support Level
- MDXG $9.07
- BCAX N/A
- Resistance Level
- MDXG $9.60
- BCAX N/A
- Average True Range (ATR)
- MDXG 0.32
- BCAX 0.00
- MACD
- MDXG -0.16
- BCAX 0.00
- Stochastic Oscillator
- MDXG 14.05
- BCAX 0.00
About MDXG MiMedx Group Inc
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.